Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KALEAD: Kaletra and Tenofovir Dual Therapy in Treatment-Naive HIV-1 Patients
NCT00234910Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jan 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Antiviral efficacy by HIV RNA at 72 weeks and Incidence of adverse events at 72 weeks. Started Jan 2005; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00234910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234910.